Hypoxia inducing factor-1α regulates tumor necrosis factor-related apoptosis-inducing ligand sensitivity in tumor cells exposed to hypoxia

Biochemical and Biophysical Research Communications

Volumn 399, Issue 3, 2010, Pages 379-383

  Jeong, Jae Kyo ^a   Moon, Myung Hee ^a   Seo, Jae Suk ^a   Seol, Jae Won ^a   Park, Sang Youel ^a   Lee, You Jin ^a  

^a Chonbuk National University   (South Korea)

Author keywords

HIF 1 ; Hypoxia; TRAIL

Indexed keywords

DEFEROXAMINE; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P53; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HYPOXIA; LUNG CANCER; NEUROBLASTOMA; PRIORITY JOURNAL; RNA INTERFERENCE; STOMACH CANCER; UTERINE CERVIX CANCER;

ANAEROBIOSIS; APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIGANDS; NEOPLASMS; OXYGEN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77956176175     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.07.082     Document Type: Article

References (24)

1. Srivastava R.K. Intracellular mechanisms of TRAIL and its role in cancer therapy. Mol. Cell Biol. Res. Commun. 2000, 4:67-75.
2. Almasan A., Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003, 14:337-348.
3. Pavet V., Beyrath J., Pardin C., Morizot A., Lechner M.C., Briand J.P., Wendland M., Maison W., Fournel S., Micheau O., Guichard G., Gronemeyer H. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res. 2010, 70:1101-1110.
4. Mellier G., Huang S., Shenoy K., Pervaiz S. TRAILing death in cancer. Mol. Aspects Med. 2010, 31:93-112.
5. Carter B.Z., Mak D.H., Schober W.D., Dietrich M.F., Pinilla C., Vassilev L.T., Reed J.C., Andreeff M. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008, 111:3742-3750.
6. Weinmann L., Wischhusen J., Demma M.J., Naumann U., Roth P., Dasmahapatra B., Weller M. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2008, 15:718-729.
7. Mahalingam D., Szegezdi E., Keane M., Jong S., Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL?. Cancer Treat. Rev. 2009, 35:280-288.
8. Selvendiran K., Bratasz A., Kuppusamy M.L., Tazi M.F., Rivera B.K., Kuppusamy P. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int. J. Cancer 2009, 125:2198-2204.
9. Park S.Y., Billiar T.R., Seol D.W. Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand, TRAIL. Biochem. Biophys. Res. Commun. 2002, 291:150-153.
10. Adams J.M., Difazio L.T., Rolandelli R.H., Lujan J.J., Hasko G., Csoka B., Selmeczy Z., Nemeth Z.H. HIF-1: a key mediator in hypoxia. Acta Physiol. Hung. 2009, 96:19-28.
11. Hu Y., Kirito K., Yoshida K., Mitsumori T., Nakajima K., Nozaki Y., Hamanaka S., Nagashima T., Kunitama M., Sakoe K., Komatsu N. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol. Cancer Ther. 2009, 8:2329-2338.
12. Kaelin W.G. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 2009, 115:2262-2272.
13. Poon E., Harris A.L., Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert. Rev. Mol. Med. 2009, 11:e26.
14. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998, 12:149-162.
15. Koumenis C., Alarcon R., Hammond E., Sutphin P., Hoffman W., Murphy M., Derr J., Taya Y., Lowe S.W., Kastan M., Giaccia A. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell Biol. 2001, 21:1297-1310.
16. Mayes P.A., Campbell L., Ricci M.S., Plastaras J.P., Dicker D.T., El-Deiry W.S. Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biol. Ther. 2005, 4:1068-1074.
17. Zhao Y., Chen X.Q., Du J.Z. Cellular adaptation to hypoxia and p53 transcription regulation. J. Zhejiang Univ. Sci. B 2009, 10:404-410.
18. Yang J., Ahmed A., Poon E., Perusinghe N., de Haven Brandon A., Box G., Valenti M., Eccles S., Rouschop K., Wouters B., Ashcroft M. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol. Cell Biol. 2009, 29:2243-2253.
19. Seo J.S., Seol J.W., Moon M.H., Jeong J.K., Lee Y.J., Park S.Y. Hypoxia protects neuronal cells from human prion protein fragment-induced apoptosis. J. Neurochem. 2010, 112:715-722.
20. Seol J.W., Chaudhari A.A., Lee Y.J., Kang H.S., Kim I.S., Kim N.S., Park J.H., Kim T.H., Seol D.W., Park S.Y. Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol. Rep. 2007, 18:523-529.
21. Lee S.H., Koo K.H., Park J.W., Kim H.J., Ye S.K., Park J.B., Park B.K., Kim Y.N. HIF-1 is induced via EGFR activation and mediates resistance to anoikis-like cell death under lipid rafts/caveolae-disrupting stress. Carcinogenesis 2009, 30:1997-2004.
22. Ryan H.E., Lo J., Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998, 17:3005-3015.
23. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio-resistance. Novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric oxide 2008, 19:205-216.
24. Pei G.T., Wu C.W., Lin W.W. Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1alpha-mediated mechanism. Biochem. Biophys. Res. Commun. 2010, 391:1274-1279.